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comes (Clinical Global Impression Scale [CGI], Hamilton Anxi-
ety Rating Scale [HAM-A], number of panic attacks, Mobility 
Inventory [MI], Panic and Agoraphobia Scale, Beck Depres-
sion Inventory) at post-treatment and follow-up (categorical). 
Further, the role of severity of depressive symptoms on anxi-
ety/depression outcome measures was examined (dimen-
sional).  Results: Comorbid depression did not have a signifi-
cant overall effect on anxiety outcomes at post-treatment 
and follow-up, except for slightly diminished post-treatment 
effect sizes for clinician-rated CGI (p = 0.03) and HAM-A (p = 
0.008) when adjusting for baseline anxiety severity. In the di-
mensional model, higher baseline depression scores were
associated with lower effect sizes at post-treatment (except 
for MI), but not at follow-up (except for HAM-A). Depressive 
symptoms improved irrespective of the presence of depres-
sion.  Conclusions: Exposure-based CBT for primary PD/AG 
effectively reduces anxiety and depressive symptoms, irre-
spective of comorbid depression or depressive symptom-
atology.  Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: Controversy surrounds the questions whether 
co-occurring depression has negative effects on cognitive-
behavioral therapy (CBT) outcomes in patients with panic dis-
order (PD) and agoraphobia (AG) and whether treatment for 
PD and AG (PD/AG) also reduces depressive symptomatol-
ogy.  Methods: Post-hoc analyses of randomized clinical trial 
data of 369 outpatients with primary PD/AG (DSM-IV-TR cri-
teria) treated with a 12-session manualized CBT (n = 301) and 
a waitlist control group (n = 68). Patients with comor-
bid depression (DSM-IV-TR major depression, dysthymia, or 
both: 43.2% CBT, 42.7% controls) were compared to patients 
without depression regarding anxiety and depression out-
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 Introduction 
 Cognitive-behavioral therapy (CBT) specifically tar-
geting anxiety-related cognitions and behavior is effica-
cious for panic disorder (PD) with and without agora-
phobia (AG)  [1–3] and considered as a first-line treat-
ment  [4, 5] . There is controversy, however, regarding the 
question of whether (1) comorbid depression negatively 
affects CBT outcomes in patients with PD and AG (PD/
AG), and (2) CBT specifically designed for PD/AG also 
effectively reduces depressive symptomatology. These 
questions are important for clinical care given the epi-
demiological evidence that anxiety disorders are risk 
factors for depression and typically precede the onset of 
depression  [6–13] , and that depression is a frequent co-
morbid complication of PD/AG patients  [14–19] . Co-
morbid depression in PD/AG is associated with in-
creased disability  [15] , higher overall illness severity 
 [20–22] and more severe panic-related symptoms  [23] . 
The question to what degree comorbid depression and 
severity of depression affects treatment response and 
long-term outcome is understudied, in part because 
randomized studies often exclude PD/AG with concur-
rent depression.
 The few available studies reveal contradictory find-
ings. Early studies suggested that comorbid depression 
does not negatively impact CBT for PD with or without 
AG  [24, 25] . Similarly, naturalistic studies  [22, 26–28] , 
CBT studies  [21, 23,  29,  30] and pharmacological studies 
 [31, 32] did not find significant effects of comorbid de-
pression on treatment response or long-term outcome. I n 
contrast, poorer post-treatment outcomes for PD patients 
with and without AG suffering from comorbid depres-
sion were reported from some naturalistic  [33–37] , one 
CBT  [38] and one pharmacotherapy study  [39] . Further-
more, Brown et al.  [40] (CBT) and Pollack et al.  [41] 
(pharmacotherapy) reported that depression comorbidi-
ty was associated with poorer treatment response for PD, 
but not worse long-term outcome.
M ost studies addressing these issues were under-
powered to systematically test for possible effects of de-
pression. The contradictory findings may also be due to 
differences in methodology such as diagnostic crite - 
ria, outcome measures, and exclusion criteria. Further, 
dimensional measures of depression have rarely been 
 utilized. Two noteworthy exceptions are the studies of 
McLean et al.  [21] who excluded patients with any current 
axis I disorder other than PD, AG or depression, and 
 Keijsers et al.  [42] , who suggested that the initial level of 
depression predicted higher frequency of panic attacks 
and physical panic symptoms, but not agoraphobic avoid-
ance behavior at the end of treatment.
 The question of whether CBT for PD/AG effectively 
reduces depressive symptomatology is also a matter of 
debate. Tsao et al.  [30, 43, 44] suggested that CBT for PD/
AG significantly reduces overall comorbidity, including 
depression. However, their sample was small (n = 51) and 
the depression subgroup (n = 9) was insufficiently sized. 
A recent multicenter CBT trial for PD with or without AG 
by Allen et al.  [23] observed reductions in depressive 
symptomatology without specifically targeting depres-
sive conditions. Rates of major depressive disorder de-
creased, but the changes were nonsignificant. No signifi-
cant reductions of depressive symptomatology were ob-
served in the CBT treatment studies of McLean et al.  [21] 
and Woody et al.  [45] ; however, they excluded patients 
with any comorbid axis I disorder other than PD, AG or 
depression. 
 Given these inconclusive findings, the current study 
examined: (1) whether comorbid depressive disorder 
(categorical) and the severity of depressive symptomatol-
ogy (dimensional) are associated with poorer treatment 
response and long-term outcome of CBT for PD/AG as 
measured by clinician-rated anxiety scales (Hamilton 
Anxiety Rating Scale, Clinical Global Impression Scale) 
and self-reported anxiety measures (number of panic at-
tacks, Mobility Inventory, Panic and Agoraphobia Scale), 
and (2) whether CBT for PD/AG also reduces the severi-
ty of co-occurring depressive symptoms without using 
explicit intervention components targeting depressive 
symptomatology.
 Methods 
 Sample 
 Data were derived from a randomized clinical trial data of 369 
PD/AG patients treated with two state-of-the-art variants of CBT 
(with and without therapist-guided in situ exposure) for PD/AG 
(n = 301) and a waitlist control group (WL; n = 68) sampled from 
eight psychological and psychiatric outpatient study centers in 
Germany. Further study details are described elsewhere  [3, 46, 
47] . Individuals were eligible for original trial inclusion if they 
met DSM-IV-TR diagnostic criteria for PD/AG as the clinician-
rated primary diagnosis, scored  6 18 on the Hamilton Anxiety 
Scale, and  6 4 on the Clinical Global Impression Scale. Exclusion 
criteria were noncompliance with the study schedule/require-
ments (n = 13), clinically significant suicidal intent (n = 0), meet-
ing diagnostic criteria for any psychotic or bipolar disorder (n = 
2), borderline personality disorder (n = 0), current alcohol depen-
dence (n = 2), or having a medical condition that could explain 
the patient’s symptoms (n = 4). Unlike other clinical randomized 
trials, other comorbid diagnoses were allowed. Patients had to 
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agree to discontinue all psychopharmacological medication (in-
cluding antidepressants and anxiolytics). Patients on psycho-
pharmacological medication underwent a washout period prior 
to baseline.
 For the present post-hoc analyses, all 369 patients with PD/AG 
were grouped into two categories: (1) with or (2) without comor-
bid depression (DSM-IV-TR major depressive episode and/or dys-
thymia). 43.2% (n = 130) of patients in the CBT treatment arms 
and 42.7% (n = 29) in the WL met criteria for MDE, dysthymia or 
both.
 Assessments 
 Diagnoses were established face-to-face at baseline (BL) and 
6-month follow-up (FU-6) using the computer-assisted version of 
the standardized Composite International Diagnostic Interview 
(CAPI-WHO-CIDI; DIAX-CIDI version)  [48] . All diagnoses were 
subsequently verified by the clinical director of each site. Course 
and outcome assessments were conducted at BL, intermediate, 
post-treatment assessment and at FU-6. Primary outcome mea-
sures were the Hamilton Anxiety Scale (HAM-A; total score, so-
matic and psychic anxiety subscores) using the Structured Inter-
view Guide  [49, 50] , the Clinical Global Impression Scale – Sever-
ity Subscale (CGI)  [51] , and patients self-report measures of the 
Panic and Agoraphobia Scale (PAS)  [52] , the number of panic at-
tacks as reported in the PAS, and agoraphobic avoidance (Mobil-
ity Inventory [MI])  [53] . Depressive symptomatology was assessed 
by the Beck Depression Inventory, 2nd Edition (BDI-II, German 
version)  [54] .
 Treatment Conditions 
 Treatment was based on a 12-session manualized CBT treat-
ment protocol, carried out over 6 weeks, and followed by two 
booster sessions  [3, 46, 55] . CBT consisted of modules of psycho-
education, functional analysis of patients’ symptoms and associ-
ated coping behaviors, rationale for exposure (i.e. sufficiently long 
and repeated exposure to feared stimuli without utilization of 
safety behaviors leads to fear reduction), interoceptive exposure, 
standardized in situ exposure (i.e. bus, shopping mall and forest), 
anticipatory anxiety, individualized in situ exposure (i.e. of the 
patients’ most feared situations), and relapse prevention. The 
study compared two CBT variants (not examined in this paper), 
which differed exclusively with respect to the delivery, not in con-
tent, of the in situ exposure component. In situ exposures were 
either accompanied by the therapist (T+; n = 163) or thoroughly 
planned in the therapy room including mental rehearsal, antici-
pation of problems and with identical instructions not to use safe-
ty behaviors (T–; n = 138). In the T– variation, therapists did not 
leave the therapy room, but patients were instructed to engage in 
the in situ exposure exercises in the interval between the therapy 
sessions. Although there were some advantages for T+, both treat-
ment conditions were highly efficacious and efficient  [3, 55, 65] . 
For the current analysis T+ and T– were collapsed together and 
are referred to as the CBT treatment group (n = 301).
 Statistical Analyses  
 Effect sizes (ES) in therapy outcomes between study patients 
with and without comorbid depression were calculated as mean 
differences of outcome scores at post-treatment and FU-6, each 
divided by the pooled standard deviation at baseline (Cohen’s d). 
This was the dependent variable of two sets of linear regression 
models: nonadjusting (model I) and adjusting for the baseline val-
ue of the respective outcome and the treatment condition (model 
II). Differences in binary outcomes were calculated with odds ra-
tios (ORs) from logistic regressions. 
 The last observation carried forward (LOCF) method was ap-
plied in order to not lose observations due to dropout and to yield 
conservative outcome estimates. This should also lead to conser-
vative estimates in differences in outcomes according to depres-
sion status at baseline (because the lack of difference at baseline 
achieved by adjusting for the baseline value of the outcome is car-
ried forward). Statistical significance was considered at the 0.05 
level. Completer (n = 242 at post-treatment; dropout rates were 
comparable for patients with [19.3%] and without [20.0%] comor-
bid depression) analyses were also conducted (available upon re-
quest).
 The associations between dimensional depression severity 
(BDI-II) at BL and ES on outcome measures from BL to post-treat-
ment or FU-6 were examined nonparametrically (local polyno-
mial approximation  [56] ) for each outcome measure separately. 
Increasing/decreasing curves indicate lower/higher ES on the 
outcome measures with increasing BDI-II ( fig. 1 ). To avoid over-
lapping points in the figures, some normally distributed noise 
(mean 0, SD 0.15–0.25) was added to the outcomes. This was not 
applied to the calculation of the fitted curves. We fitted (a) regres-
sions with the linear predictor BDI-II at BL to assess overall as-
sociations, and (b) regressions with both the linear and the 
squared BDI-II to see whether deviations from linearity as sug-
gested by some graphs were significant. Both models were repeat-
ed while adding the main effect term of depression at BL as well 
as the interaction term for depression  ~ BDI-II and, on top of that, 
the interaction term for depression  ~ squared BDI-II. To ease the 
language we use the term ‘effect’ to denote associations, but do not 
refer to causal relationships.
 Results 
 Characteristics Comparison Groups 
 Patients with and without comorbid depression in 
both the CBT and the WL group were comparable with 
regard to psychosocial and clinical characteristics, with 
few exceptions ( table  1 ). Rates of comorbid depression 
were also similar in the CBT and WL group. In the CBT 
group, 130/301 (43.2%) patients met criteria for a comor-
bid depressive disorder at BL (MDE alone n = 80 [26.6%], 
dysthymia alone n = 19 [6.3%], MDE and dysthymia n = 
31 [10.3%]). In the WL 29/68 (42.7%) of patients met cri-
teria for comorbid depression (MDE alone n = 16 [23.5%], 
dysthymia alone n = 5 [7.4%], MDE and dysthymia n = 8 
[11.8%]). 
 In the CBT group, PD/AG patients with comorbid de-
pression were younger ( table  1 ), had more frequently 
other comorbid conditions (most frequently specific 
phobia [71.1%] and social phobia [41.9%]), reported ear-
lier onset of PD/AG and scored significantly higher on 
 Emmrich et al. Psychother Psychosom 2012;81:161–172164
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the baseline BDI-II measure than those without depres-
sion. Except for number of panic attacks and the CGI 
they also scored higher on the dimensional baseline 
anxiety measures. The differences for the HAM-A re-
mained even when excluding the item on depressive 
mood. In the WL, patients with comorbid depression 
revealed significantly higher CGI and BDI-II scores 
only. Out of the patients with comorbid MDE in the CBT 
group 33.3% reported a single episode (WL 24.1%), 51.4% 
multiple episodes (WL 10.8%) and 10.8% a chronic 
course of depression (WL 10.3%).
 Effect of Depression Comorbidity (Categorical) on 
Anxiety Outcomes  
 Model I (unadjusted) revealed consid erable and signif-
icant post-treatment-BL and FU-6-BL symptom reduc-
tions in all anxiety outcome measures for CBT with no 
significant differences between patients with and without 
depression except for the somatic anxiety subscore of the 
HAM-A which decreased more in the noncomorbid de-
pression group (p = 0.04) ( table 2 , upper part). At FU-6, 
ES increased in both groups, revealing no significant dif-
ferences between those with and without depression, but 
again with the exception of the somatic anxiety subscore 
of the HAM-A (p = 0.02). For the WL no significant post-
treatment-BL symptom reductions (ES by outcome mea-
sure ranges from a low of 0.02 [BDI-II] to a high of –0.85 
[CGI]) or differences in ES for patients with or without 
comorbid depression were observed.
 Model II (adjusted;  table 2 , lower part) generally re-
vealed similar findings; however there were significantly 
lower post-treatment-BL ES in the clinician-rated CGI
(p = 0.03), the HAM-A total score (p = 0.008) and the 
HAM-A subscores (somatic anxiety p = 0.001; psychic 
Table 1.  Comparison groups: baseline and clinical characteristics
Sample characteristics CBT group (n = 301) W L (n = 68)
PD/AG with 
comorbid depres-
sion* (n = 130)
PD/AG without 
comorbid depres-
sion* (n = 171)
compari-
son**, 
p value
PD/AG with 
comorb id depres-
sion* (n = 29)
PD/AG without 
comorbid depres-
sion* (n = 39)
compari-
son**, 
p value
Age 33.7810.7 36.8810.5 0.01 38.2812.1 33.7810.1 0.1
Gender
Male 28 (21.5) 45 (26.3) ref. 6 (20.7) 8 (20.5) ref.
Female 102 (78.5) 126 (73.7) 0.34 23 (79.3) 31 (79.5) 0.99
Number of other mental diagnoses***
     None 8 (6.2) 25 (14.6) ref. 3 (10.3) 4 (10.3) ref.
1–2 63 (48.5) 102 (59.7) 0.13 13 (44.8) 23 (59.0) 0.74
3–4 51 (39.2) 38 (22.2) 0.002 10 (34.5) 10 (25.6) 0.75
5+ 8 (6.2) 6 (3.5) 0.04 3 (10.3) 2 (5.1) 0.56
Age at first onset of PD/AG 23.289.2 25.788.9 0.04 24.787.4 27.6816.6 0.35
Years since first onset of PD/AG 11.1810.1 12.0810.2 0.49 11.9810.8 9.988.7 0.46
Age at first onset of depression* 26.2810.1 – – 28.3811.6 – –
Years since first onset of depression* 7.889.9 – – 9.6811.0 – –
HAM-A
Total score 25.487.1 22.087.0 <0.001 24.886.5 24.186.0 0.67
Somatic anxiety 10.984.9 9.884.4 0.04 10.783.8 11.084.1 0.74
Psychic anxiety 14.583.9 12.284.1 <0.001 14.183.7 13.183.3 0.29
CGI 5.380.7 5.280.7 0.16 5.480.6 5.180.7 0.02
Number of panic attacks (last week) 2.882.5 2.482.3 0.22 2.582.0 2.382.2 0.70
MI 3.180.8 2.980.8 0.008 3.180.9 2.981.0 0.58
PAS 29.989.3 26.2810.0 0.001 29.489.7 26.489.3 0.20
BDI-II 20.588.4 13.487.5 <0.001 22.2810.0 12.986.4 <0.001
* 1 2-month prevalence of MDE and/or dysthymia at baseline; ** with vs. without depression (mean difference/odds ratio calcu-
lated from linear/logistic regression); *** additional to PD/AG and MDE/dysthymia; exclusion criteria were (a) comorbid psychotic 
or bipolar I disorder, (b) current alcohol dependence/current abuse or dependence for benzodiazepines and other psychoactive sub-
stances, (c) current suicidal intent, (d) borderline personality disorder. Results are presented as means 8 SD or numbers with percent-
ages in parentheses.
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anxiety p = 0.003) among patients with comorbid depres-
sion. In the FU-6-BL comparison this difference was at-
tenuated, remaining significant only for the HAMA (to-
tal score p = 0.003; somatic anxiety p  ! 0.001; psychic 
anxiety p = 0.004). 
 Effects of Baseline Depressive Symptomatology 
(Dimensional) on Anxiety Outcomes 
 Depression scores (as measured by the BDI-II) corre-
lated moderately and differentially across the anxiety 
measures (Pearson r = 0.09–0.44) indicating that differ-
ent constructs (depression vs. anxiety) were measured. 
 Figure 1 depicts the differential dimensional relationship 
of depressive symptoms with the outcome measures for 
the post-treatment-BL effects sizes and the FU-6-BL 
comparisons, supplemented by the overall regression 
means for patients with and without depression. No sig-
nificant effects were observed in the WL. Following re-
sults refer to the active CBT condition.
 Associations between Depressive Symptomatology 
(Dimensional) and Anxiety Outcomes among 
CBT-Treated Patients 
 Taking patients with and without depression together, 
model I (unadjusted,  fig. 1 a–e) revealed no significant ef-
fects of baseline depression severity on most anxiety out-
comes, with two noteworthy exceptions: first, baseline 
BDI-II was significantly associated with poorer long-
term outcome in the PAS total score, meaning that an 
increased depression score of 1 SD on the baseline BDI-II 
predicted lower FU-6-BL ES (effect size difference [ESD] 
= 0.17; 95% CI 0.04 to 0.30; p = 0.011). Second, for number 
of panic attacks a curvilinear association was observed 
between BL and post-treatment (squared term indicating 
more favorable ES with increasing BDI-II = –0.13; 95% CI 
–0.22 to 0.03; p = 0.007). When adjusting for baseline se-
verity, model II revealed that the BDI-II overall signifi-
cantly predicted only the post-treatment-BL ES, on most 
anxiety outcome measures, with the exception of agora-
Table 2.  Anxiety and depression outcomes by baseline depression comorbidity (CBT group, n = 301)
Posttreatment minus BL FU-6 minus BL
PD/AG with 
comorbid 
depression* 
(n = 130)
PD/AG without
comorbid 
depression* 
(n = 171)
between-group 
comparison, 
ESD** (95% CI)
p 
value
PD/AG with 
comorbid 
depression* 
(n = 13)
PD/AG without
comorbid 
depression* 
(n = 171)
between-group 
comparison, 
ESD** (95% CI)
p
value
Model I (unadjusted)***
Anxiety outcome measures
HAM-A, total score –1.76 (1.65) –2.07 (1.41) 0.30 (–0.05 to 0.65) 0.09 –2.06 (1.86) –2.41 (1.40) 0.35 (–0.02 to 0.72) 0.06
HAM-A, somatic anxiety –0.80 (1.25) –1.07 (1.09) 0.27 (0.01 to 0.54) 0.04 –0.94 (1.41) –1.28 (1.08) 0.34 (0.05 to 0.62) 0.02
HAM-A, psychic anxiety –1.80 (1.56) –1.95 (1.41) 0.15 (–0.19 to 0.49) 0.38 –2.09 (1.71) –2.25 (1.39) 0.16 (–0.19 to 0.51) 0.37
CGI –2.09 (1.79) –2.37 (1.69) 0.28 (–0.12 to 0.67) 0.17 –3.04 (2.40) –3.26 (2.05) 0.23 (–0.28 to 0.73) 0.38
Number of panic attacks –0.61 (1.04) –0.54 (0.99)      –0.07 (–0.30 to 0.16) 0.56 –0.81 (1.12) –0.73 (0.99)    –0.08 (–0.32 to 0.16) 0.50
MI***** –1.08 (1.02) –1.03 (0.80)      –0.04 (–0.26 to 0.17) 0.69 –1.47 (1.23) –1.33 (0.94)    –0.14 (–0.40 to 0.11) 0.27
PAS –1.31 (1.04) –1.18 (1.01)      –0.13 (–0.36 to 0.11) 0.29 –1.77 (1.27) –1.53 (1.00)    –0.24 (–0.49 to 0.02) 0.07
Depression outcome measure
BDI-II –0.93 (1.04) –0.66 (0.85)      –0.17 (–0.49 to –0.06) 0.01 –1.22 (1.16) –0.76 (0.89)    –0.45 (–0.69 to –0.22) <0.001
Model II (adjusted)****
Anxiety outcome measures
HAM-A, total score –1.67 (0.13) –2.14 (0.11) 0.47 (0.13 to 0.82) 0.008 –1.94 (0.14) –2.50 (0.12) 0.57 (0.20 to 0.93) 0.003
HAM-A, somatic anxiety –0.71 (0.10) –1.14 (0.08) 0.44 (0.18 to 0.69) 0.001 –0.84 (0.10) –1.35 (0.09) 0.51 (0.24 to 0.79) <0.001
HAM-A, psychic anxiety –1.61 (0.12) –2.10 (0.11) 0.49 (0.16 to 0.82) 0.003 –1.89 (0.13) –2.40 (0.11) 0.51 (0.17 to 0.85) 0.004
CGI –2.01 (0.14) –2.43 (0.13) 0.41 (0.04 to 0.79) 0.03 –2.94 (0.18) –3.34 (0.16) 0.40 (–0.08 to 0.88) 0.10
Number of panic attacks –0.55 (0.06) –0.58 (0.05) 0.03 (–0.13 to 0.19) 0.70 –0.74 (0.05) –0.78 (0.04) 0.05 (–0.08 to 0.18) 0.47
MI***** –1.02 (0.08) –1.08 (0.07) 0.07 (–0.14 to 0.28) 0.52 –1.39 (0.09) –1.40 (0.08) 0.00 (–0.24 to 0.25) 0.97
PAS –1.20 (0.08) –1.27 (0.07) 0.07 (–0.14 to 0.28) 0.51 –1.64 (0.09) –1.64 (0.08) 0.00 (–0.23 to 0.23) 0.99
Depression outcome measure
BDI-II –0.71 (0.08) –0.83 (0.07) 0.12 (–0.10 to 0.33) 0.28 –0.94 (0.08) –0.98 (0.07) 0.04 (–0.19 to 0.26) 0.75
* M DE or dysthymia, 12-month diagnosis at baseline; ** effect size difference calculated from linear regression, >0 means depression predicts worse 
outcome (shifts decrease in outcome toward 0); *** ES (SD) unless indicated otherwise; **** predicted values (evaluated at means of predictors with stan-
dard error of prediction); ***** with comorbid depression: n = 120; without comorbid depression: n = 152.
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phobic avoidance (MI). Higher baseline BDI-II scores 
were associated with lower post-treatment-BL ES in the 
HAM-A (total score: ESD = –0.40; 95% CI –0.58 to –0.21; 
p  ! 0.001; somatic anxiety: ESD = –0.27; 95% CI –0.39 to 
–0.15; p  ! 0.001; psychic anxiety: ESD = –0.40; 95% CI 
–0.58 to –0.23; p  ! 0.001), CGI (ESD = –0.22; 95% CI 
–0.41 to –0.03; p = 0.03), number of panic attacks (ESD = 
–0.10; 95% CI –0.18 to –0.01; p = 0.02) and the PAS
(ESD = –0.14; 95% CI –0.25 to –0.03; p = 0.02). At FU-6 
though, associations remained significant only for the 
HAM-A (total score: ESD = –0.31; 95% CI –0.51 to –0.11; 
p = 0.003; somatic anxiety: ESD = –0.21; 95% CI –0.34 to 
–0.08; p  ! 0.001; psychic anxiety: ESD = –0.31; 95% CI 
–0.49 to –0.12; p  ! 0.001). 
 Noteworthy, patients with extremely high BDI-II 
scores at BL seemed to have more panic attacks at post-
treatment/FU-6 than at BL. However, the low number of 
patients with very high BDI-II scores does not allow fur-
ther testing or definite conclusions.
 Associations between Depressive Symptomatology 
(Dimensional) and Anxiety Outcomes as a Function 
of Depression Comorbidity (Categorical) 
 The slope and curvature of the curves on the dimen-
sional relationship of depressive symptoms with the out-
come measures ( fig. 1 ) were not significantly different be-
tween patients with and without comorbid depression in 
both CBT and WL across any anxiety outcome measure. 
These results were observed despite indications that 
among patients with comorbid depression, those with the 
most severe depressive symptoms at BL had slightly low-
er ES at post-treatment. Effects appear to attenuate at 
FU-6 with one exception (number of panic attacks). 
 Effects of CBT for PD/AG on Depressive 
Symptomatology (Dimensional) among Patients 
with vs. without Comorbid Depression 
 ES in the CBT group reveal a substantial reduction of 
depressive scores during treatment that is maintained 
and even extended through the follow-up period. In both 
the unadjusted and adjusted models, patients with co-
morbid depression in the CBT group revealed greater im-
provement in BDI-II at post-treatment (ESD = –0.27; 95% 
CI –0.49 to –0.06; p = 0.01) and FU-6 (ESD = –0.45; 95% 
CI –0.69 to –0.22; p  ! 0.001) ( table 2 ). However, patients 
with comorbid depression still had significantly higher 
BDI-II scores at post-treatment than patients without co-
morbid depression (12.8 vs. 7.6; mean difference on un-
standardized BDI-II [MD] = 5.23; 95% CI 3.25 to 7.2; p  ! 
0.001) and FU-6 (10.3 vs. 6.6; MD = 3.64; 95% CI 1.67 to 
5.61; p  ! 0.001). In contrast, the WL revealed no reduction 
of depressive symptoms. 
 Effects of CBT for PD/AG on Depressive 
Symptomatology (Dimensional) Contingent on 
Baseline Depression Severity 
 Dimensional reduction in BDI-II was most pro-
nounced among those with the highest baseline BDI-II 
scores ( fig. 1 f). Higher BDI-II predicted overall higher ES 
on the BDI-II at post-treatment (model I: ESD = 0.42; 95% 
CI 0.33 to 0.52; p  ! 0.001/model II: ESD = 0.42; 95% CI 
0.32 to 0.52; p  ! 0.001 per standard deviation more on 
baseline BDI-II) and FU-6 (model I: ESD = 0.55; 95% CI 
0.45 to 0.65; p  ! 0.001/model II: ESD = 0.54; 95% CI 0.44 
to 0.65; p  ! 0.001). Slope and curvature of the curves did 
not differ between CBT patients with or without comor-
bid depression. However, overall curvilinear association 
indicating lower slope with higher baseline BDI-II sever-
ity was found at post-treatment (model I: ESD = –0.08; 
95% CI –0.16 to –0.01; p = 0.033/model II: ESD = –0.08; 
95% CI –0.16 to –0.01; p = 0.033), but not at FU-6. 
 Discussion 
 Prior research revealed inconsistent and inconclusive 
findings regarding (1) whether comorbid depression dis-
order (categorical) and the severity of depressive symp-
tomatology (dimensional) affect post-treatment/follow-
up anxiety outcomes of patients with PD/AG treated with 
CBT and (2) whether CBT for PD/AG also effectively re-
duces nontargeted depressive symptomatology. These 
clinically important questions were examined with data 
from a multicenter clinical CBT trial of 369 outpatients 
with a primary DSM-IV-TR diagnosis of PD/AG. CBT for 
PD/AG was highly effective for the targeted primary anx-
iety outcomes measures irrespective of the presence of a 
comorbid depression disorder (categorical) or the sever-
ity of depressive symptomatology (dimensional). Further, 
CBT for PD/AG improved nontargeted depressive symp-
toms. Importantly, these results were found in a meth-
odologically sufficient sample characterized by a large 
sample size and substantial statistical power to examine 
these questions; categorical and dimensional examina-
tion of the effect of depression and depressive symptom-
atology; inclusion of a broad range of anxiety outcome 
measures; use of a state-of-the-art CBT manual for PD/
AG that specifically focuses on anxiety without address-
ing depressive symptomatology, and the use of a control 
group without treatment. The present study did not use 
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comorbid depression as an exclusion criterion and en-
rolled patients were treated across eight psychological 
and psychiatric treatment centers. As such, the character-
istics of patients in this study can be considered typical 
for help seeking patients with PD/AG in outpatient set-
tings.
 As expected from epidemiological surveys, a substan-
tial proportion of our patients with primary PD/AG  [66, 
67] suffered from a comorbid depressive disorder (MDE 
and/or dysthymia; 43%). This rate was somewhat higher 
than those found in several other treatment studies of PD/
AG (13%  [40] , 23%  [37] , 21%  [43] , 18%  [30] ) or PD with or 
without AG (19%  [23] , 12%  [27] , 30%  [44] ), but similar to 
the one reported by Starcevic et al. (48%)  [57] . Differences 
in rates of comorbid depression are likely due to differ-
ences in methodological factors. Patients with comorbid 
depressive disorder scored higher on the pretreatment
MI, PAS and HAM-A than patients without depression. 
Whereas the increased HAM-A findings are not straight-
forward due to strong confounding with depression-rele-
vant items (i.e. depressed mood, insomnia, poor concen-
tration), these patterns of associations may suggest that 
comorbid depression exerts its effect indirectly on actual 
or perceived behavioral consequences rather than direct-
ly on symptom expression. Agoraphobic avoidance, as 
measured by the MI, typically involves a loss or reduction 
of meaningful reinforcers for the patient that are associ-
ated with restricted mobility and disability in daily ac-
tivities. This is also supported by our finding of elevated 
baseline scores in the multidimensional PAS measure. 
Thus, we speculate that the higher MI and PAS scores at 
baseline likely represent perceived and real consequences 
of panic-associated avoidance behavior for the patient, 
whereas the increased HAM-A scores might more appro-
priately be interpreted as indicating higher overall illness 
severity  [20] . 
 Two main findings characterize the present study. 
First, overall comorbid depression does not significantly 
impact the short- and long-term (6-month) effect of CBT 
for PD/AG. Although slightly lower post-treatment effect 
sizes for clinician-rated primary outcome measures (CGI 
and HAM-A) were observed when adjusting for baseline 
anxiety severity, the effect was not substantiated by self-
report outcome measures. This effect was eliminated 
(CGI) or attenuated (HAM-A) at the FU-6. Dimensional 
analyses among cases with high baseline depressive 
symptomatology suggest the possibility of detrimental 
treatment response at post-treatment but not long-term 
(FU-6) effects on targeted primary anxiety outcomes. 
Second, CBT for PD/AG improved depressive symptoms 
in both, patients with and without diagnosable comorbid 
depression, irrespective of the severity of depression at 
baseline. This occurred without specifically targeting de-
pression in therapy. 
 These main findings have important implications for 
clinical care. CBT for PD/AG is sometimes assumed to be 
effective primarily for monosymptomatic patients with 
mild illness severity. Our findings provide evidence that 
overall CBT for PD/AG is effective irrespective of comor-
bid depression or severity of depressive symptomatology. 
In clinical routine, many clinicians tend to modify their 
therapeutic strategy by addressing depressive symptoms 
when deemed necessary. Practitioners thereby deviate 
from established state-of-the-art manuals for PD/AG. Al-
though it remains an empirical question as to whether 
these findings could have otherwise been further bol-
stered, our results strongly suggest that retaining a con-
sistent focus on the primary anxiety diagnosis does not 
negatively affect the short- and long-term anxiety out-
comes and also reduces depressive symptomatology. CBT 
is a first-line treatment for PD/AG, can be administered 
alone, and needs to be further investigated given the un-
clear role of psychopharmacotherapy  [58, 59] .
 Effects of Depression/Depressive Symptomatology on 
Anxiety Outcomes 
 Although the results suggest that depression does not 
negatively affect primary anxiety outcome it is impor-
tantly to note that the number of PD/AG patients with 
extremely elevated depression scores was relatively lim-
ited. We cannot exclude the possibility of different treat-
ment needs among the few PD/AG patients with the most 
severe depression. Findings that primary PD/AG patients 
with the most severe baseline depressive symptoms had 
somewhat attenuated responses on some measures – at 
least in the post-treatment-BL period – raise the question 
of whether this subgroup may require additional inter-
ventions that specifically target depression  [60] . 
 Our findings also highlight the importance of exam-
ining treatment effects and follow-up outcomes separate-
ly by outcome measure. Patients with depression comor-
bidity, compared to those without, revealed no differ-
ences in effect sizes on any self-report questionnaires. 
However, depression comorbidity was associated with 
lower treatment response on clinician-rated measures – 
at least when the analyses were adjusted for baseline levels 
of the respective outcome. It is likely that clinicians put a 
greater weight on the depressive symptomatology and its 
consequences, while the patient does not seem to take this 
equally into account. As differential depression effects of 
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clinician ratings were attenuated at follow-up, we inter-
pret our findings overall as reflecting evidence that PD/
AG patients with comorbid depression benefit similarly 
from treatment as patients without depression. This con-
clusion is in line with interpretations from studies that 
found positive treatment effects are retained or even en-
hanced in the follow-up period  [21–26, 28, 30, 31] . 
 Effects of CBT for PD/AG on Depressive 
Symptomatology 
 Concerning the question of whether CBT for PD/AG 
also effectively reduces the severity of nontargeted co-
occurring depressive symptoms without using explicit 
antidepressive strategies, we found remarkable and sig-
nificant effect sizes. Even for patients with comorbid de-
pression at BL the mean BDI-II values at post-treatment 
and FU-6 were within the range of no/minimal depres-
sion (0–13) according to the cut-offs of the BDI-II  [54] . 
Positive effects of CBT for PD/AG on depressive symp-
tomatology were observed in those with and those with-
out comorbid depressive disorder and continued in the 
follow-up period. Overall, these results are comparable to 
prior findings  [23, 30, 43, 44] , except for McLean et al.  [21] 
and Woody et al.  [45] , who excluded patients with any 
other comorbid axis I disorder than PD, AG or depres-
sion. This discrepancy of findings suggests possible inter-
actions between several other types of comorbidity. 
 The question why CBT for PD/AG also effectively re-
duces depression remains unclear. The lack of any im-
provement in the WL shows that it is not due to sponta-
neous remission over time. So what could be the under-
lying mechanisms of action in CBT explaining this 
remarkable effect? One possible explanation is that CBT 
simultaneously functions as a type of behavioral activa-
tion (exposure in situ and anxiety exercises with home-
work assignments), which in itself is a reasonable treat-
ment for depression  [61, 62] . Patients may also enhance 
their self-efficacy expectations or self-esteem due to the 
experiences of getting the exposure exercises done within 
the treatment for PD/AG. Detailed analysis of these issues 
is clearly needed  [63] .
 Findings must be viewed in the light of several limita-
tions. First, this study is based on post-hoc analyses of a 
clinical randomized trial that examined two variants of 
CBT for PD/AG, thus patients were not randomized based 
on the comorbid diagnostic status of depression. Second, 
possible differences in results for different types of comor-
bid major depression (single episode, recurrent, chronic, 
melancholic features) or dysthymia  [64] were not sepa-
rately considered in this paper. Third, other comorbid dis-
orders (like other anxiety disorders, axis-II disorders) 
were not considered in the present analyses but may also 
have affected treatment response on CBT for PD/AG. 
Fourth, patients were treated within academic centers ac-
cording to a manual-based CBT. Further, they had to 
agree to discontinue all psychopharmacological medica-
tion and to undergo a washout period prior to baseline. 
Exclusion criteria were explicitly bipolar affective disor-
der and suicidality. These conditions may differ from less 
controlled natural therapy settings in routine care, thus 
limiting the generalizability of our results to other set-
tings and in particular to severe and complicated forms of 
depression. And, finally, we did not differentiate the two 
variants of exposure (in situ exposure with vs. without 
therapist during exposure exercises) in the current study 
and further differentiated analyses on a possible modera-
tor function of treatment condition on the association of 
comorbid depression with treatment outcomes are war-
ranted.
 To conclude, comorbid depression, defined as meeting 
DSM-IV-TR criteria for major depression, dysthymia or 
both, overall does not significantly impact the short- and 
long-term efficacy of an exposure-based CBT for PD/AG 
patients. Similarly, the level of depressive symptomatol-
ogy does not play a meaningful role for the targeted anx-
iety outcome. This held true across various established 
anxiety outcome measures. These results are encourag-
ing, for they provide evidence that depressive patients can 
benefit from CBT for PD/AG. Indeed, the CBT treatment 
used in this study was highly effective for PD/AG and co-
occurring depressive symptomatology alike. Examina-
tion of how and why CBT or its components in particular 
contributes to the reduction in depressive symptomatol-
ogy is highly warranted to improve intervention strate-
gies.
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